MANHATTAN BIOSOLUTIONS, LLC

Biotech · Private

Genetically engineered live Mycobacterium bovis BCG bacteria expressing tumor neoantigen fragments for bladder cancer immunotherapy

Grants
$546K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Novel recombinant BCG for immunotherapy of bladder cancer$290,014
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Against COVID-19$256,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1631Quell Therapeutics——
1632Inipharm——
1633MINK THERAPEUTICS INC——
1634MANHATTAN BIOSOLUTIONS, LLC——
1635Find Genomics Inc.——
1636Amplifier Therapeutics——
1637Rapt Therapeutics—$303M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.